A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 Cells/mm3
NCT ID: NCT00001064
Last Updated: 2016-12-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
INTERVENTIONAL
2005-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Dendritic cells are a type of white blood cell used by the body to fight infection. They are instrumental in presenting antigens (such as HIV antigens) to the body's immune system. Since dendritic cells are not functioning maximally in HIV-infected patients, infusion of dendritic cells from an HIV-negative sibling may enable the affected sibling's immune system to recognize foreign particles more readily and increase immune response against the virus.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients
NCT00000824
A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects
NCT00833781
Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients
NCT00058734
Autologous Dendritic Cell Vaccine in HIV1 Infection
NCT00510497
Dendritic Cell Vaccine in HIV-1 Infection
NCT00402142
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Dendritic cells from an HIV-negative sibling are obtained and treated with various viral proteins (HIV vaccines) or immunomodulators. The treated dendritic cells are infused into the HIV-infected patient monthly for 6 months. Siblings must be able to donate on multiple occasions, and patients are followed every 2-4 weeks during the study. Patients are screened over 3 months prior to study entry.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Allogenic Dendritic Cells
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HLA A2+.
* Same cell type as donor sibling.
* CD4 count \> 350 cells/mm3.
* HIV asymptomatic status.
* No HIV antivirals during study.
* Normal labs and chest x-ray.
Donor siblings must have:
* HLA A2+.
* HIV negativity.
* Ability to donate cells on multiple occasions.
* Negative status for hepatitis B and C.
Exclusion Criteria
Excluded:
* Antiviral therapy (unless CD4 count declines to \< 350 cells/mm3).
Prior Medication:
Excluded:
* Antiviral therapy within 90 days prior to study entry.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford Univ School of Medicine
Stanford, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SPIRAT 1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.